logo
New Research Debunks Myth That Brain Cells Stop Growing After Childhood

New Research Debunks Myth That Brain Cells Stop Growing After Childhood

Gizmodo15 hours ago
You've probably heard the old canard that new brain cells simply stop forming as we become adults. But research out today is the latest to show that this isn't really true.
Scientists in Sweden led the study, published Thursday in Science. They found abundant signs of neural stem cells growing in the hippocampus of adult brains. The findings reveal more about the human brain as we get older, the researchers say, and also hint at potential new ways to treat neurological disorders.
'We've found clear evidence that the human brain keeps making new nerve cells well into adulthood,' study co-author Marta Paterlini, a neuroscientist at the Karolinska Institute in Stockholm, told Gizmodo.
This Is What Your Brain Looks Like When You Solve a Problem
This isn't the first paper to chip away at the idea of new neurons ceasing to form in adulthood (a concept not to be confused with general brain development, which does seem to reach maturity around age 30). In 2013, study researcher Jonas Frisén and his team at the Karolinska Institute concluded that substantial neuron growth—also known as neurogenesis—occurs throughout our lives, albeit with a slight decline as we become elderly. But there's still some debate ongoing among scientists. In spring 2018, for instance, two different studies of neurogenesis published a month apart came to the exact opposite conclusion.
The researchers were hoping to settle one particular aspect of human neurogenesis in adults. If we do keep growing new neurons as we age, then we should be able to spot the cells that eventually mature into neurons, neural progenitor cells, growing and dividing inside the adult brain. To look for these cells, the team analyzed brain tissue samples from people between the ages of 0 and 78 using relatively new advanced methods. These methods allowed them to figure out the characteristics of brain cells on an individual level and to track the genes being expressed by a single cell's nucleus.
All told, the researchers examined more than 400,000 individual cell nuclei from these samples. And as hoped, they found these progenitor cells along various stages of development in adult brains, including cells just about to divide. They also pinpointed the location within the hippocampus where the new cells appeared to originate: the dentate gyrus, a brain region critical to helping us form certain types of memory.
'We saw groups of dividing precursors sitting right next to the fully formed nerve cells, in the same spots where animal studies have shown adult stem cells live,' said Paterlini, a senior scientist at the Frisén lab. 'In short, our work puts to rest the long-standing debate about whether adult human brains can grow new neurons.'
Something Strange Happens to Brains During a Marathon
The findings, as is often true in science, foster more questions in need of an answer. Our adult precursor cells seem to have different patterns of gene activity compared to the cells found in pigs, mice, and other mammals with clear evidence of adult neurogenesis, for instance.
The researchers also found that some adults' brains were filled with these growing precursors, while others had relatively few. These differences—combined with the team's earlier research showing that adult neurogenesis slows down over time—may help explain people's varying risk of neurological or psychological conditions, the authors say. And likewise, finding a safe way to improve the adult brain's existing ability to grow new cells could help treat these conditions or improve people's recovery from serious head injuries.
'Although precise therapeutic strategies for humans are still being researched, the simple fact that our adult brains can generate new neurons radically changes the way we view lifelong learning, recovery from injury, and the untapped potential of neuronal plasticity,' said Paterlini.
There's plenty more to be learned about how our brains change over time. The team is planning to investigate other likely hotspots of neurogenesis in the adult brain, such as the wall of the lateral ventricles (c-shaped cavities found in each of the brain's cerebral hemispheres) and nearby regions. But we can be fairly certain that our neurons keep on growing and replacing themselves into adulthood—at least for some of us.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Radiation Bridging in CAR T: Where Are We Now?
Radiation Bridging in CAR T: Where Are We Now?

Medscape

time40 minutes ago

  • Medscape

Radiation Bridging in CAR T: Where Are We Now?

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing and doses, a radiologist cautioned hematologist colleagues . The lack of guidelines has immediate clinical implications, said John P. Plastaras, MD, PhD, professor of radiation oncology at the Hospital of the University of Pennsylvania, Philadelphia, in a presentation at 18th International Conference on Malignant Lymphoma (ICML) 2025 in Lugano, Switzerland . ' This actually just came up the other day when one of our medical colleagues said, 'I'm really worried about this patient. They're ready for CAR T cell, but I think you need to radiate this area. Can you do it a week after [therapy]?' The answer is, 'We don't know.'' On the other hand, clinicians now have clarity about safety and interaction with CAR T-cell therapy, he noted, and data is coming in rapidly. Here are some questions and answers about radiation BT: What is BT in CAR T-cell therapy? BT refers to treatment that provides a 'bridge' for patients between the components of CAR T-cell therapy. As a 2024 report about BT in hematologic cancer explained, the treatment 'is delivered after leukapheresis for CAR T-cells' — the process in which white cells are removed from a patient's blood, which is then returned to the body — 'has been completed and before lymphodepleting chemotherapy and CAR T-cell infusion.' The report said 'patients who receive BT are predominantly those with a higher disease burden and rapidly progressive disease. These patients tend to have worse overall outcomes, likely related to their aggressive underlying disease.' Where does radiation fit into BT? According to the 2024 report, 'combination chemoimmunotherapy has typically been the form of BT that is used most often.' Targeted therapy is another option, the report said, although data is from 'very small sample sizes.' And then there's radiation, which the report said is useful 'particularly in patients with limited sites of disease or patients who are at risk for structural complications such as airway compromise or renal dysfunction.' What do we know about radiation's efficacy? The first oral report on bridging radiation in CAR T-cell therapy only appeared in 2018, Plastaras said, followed by the first published report in 2019. Despite this fairly short time period, 'we are certainly seeing a lot of new data,' Plastaras said. He highlighted the newly released International Lymphoma Radiation Oncology Group (ILROG) study of radiation BT in conjunction with CAR T-cell therapy for relapsed/refractory B-cell lymphomas. The retrospective study of 172 patients at 10 institutions treated from 2018 to 2020 showed that 1- and 2-year progression-free survival (PFS) rate was 43% (95% CI, 36-51) and overall survival rate was 38% (95% CI, 30-45). In a multivariable model, comprehensive radiation BT was linked to superior PFS than focal therapy (hazard ratio, 0.38; 95% CI, 0.22-0.63; P < .001). 'Comprehensive radiation was a very strong predictor for improved PFS, but we did not see was a huge dose effect,' said Plastaras, who coauthored the study. What about toxicity? Questions about other clinical matters were resolved prior to 2022, he said, when CAR T-cell therapy was used primarily in third line and later settings . 'Does radiation cause excess toxicities?' he asked. 'A lot of the single-institution studies answered that, and I think most medical oncologists and hematologists are okay with this idea that radiation isn't causing a lot of excess toxicities.' As for whether radiation interferes with the effectiveness of CAR T-cell therapy, 'the data to this point have demonstrated that probably not,' he said. 'We've probably put that one to bed.' What do we know about treatment timing? 'The timing question is still quite open,' Plastaras said. 'How much time should there be between radiation and lympho-depleting chemotherapy? Is it better to put the radiation very close to the CAR T-cell [therapy] so this priming effect might happen, or can that happen weeks in advance? We don't know the answers to those.' According to Plastaras, researchers are still trying to understand the role radiation the consolidation period after CAR T-cell therapy. 'If we wait for day-30 PET [scan], is that OK? Do we need to wait longer? Are we going to mess up the lymph nodes that have CAR T-cells floating around in them?' What about doses and imaging? There's also a lack of insight into technical questions about radiation dose and fractionation. 'The [radiation] volume question is one of key importance. Do we just do gross disease? Do we treat all the other small spots out there, and importantly, do we treat regional nodes or not? We get these questions all the time.' The role of imaging is also unclear, he said, in terms of timing during and after bridging radiation therapy and after CAR T-cell therapy. What do we need to learn about now? Looking forward, Plastaras outlined what he called 'version 2.0' questions for the evolving field: Can radiation rebulking decrease CAR-T cell toxicities? Will very low dose 'priming' radiation affect outcomes? He highlighted other questions: Can radiation be part of a combined modality approach in limited stage relapsed/refractory disease? Should central nervous system lymphoma be treated differently? When will we get new guidelines? According to Plastaras, Memorial Sloan Kettering Cancer Center Radiology Oncologist Brandon Imber,MD, MA, in New York City, is leading a new ILROG guideline project with the intention of publishing details in the journal Blood . 'This is a work in progress,' Plastaras said. 'Our target is 2025 to at least get something submitted.'

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

Yahoo

time3 hours ago

  • Yahoo

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO BENEFIT Paris, July 4, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer (study AB22007) has been authorized by FDA and EMA (harmonized protocol approved through step 1 of Clinical Trials Information System), with a biomarker that targets patients with less advanced metastatic disease. Professor Olivier Hermine, MD, President of the Scientific Committee of AB Science and member of the Académie des Sciences in France said, 'The authorization of our confirmatory Phase 3 study by both the FDA and EMA represents a critical milestone for masitinib in metastatic castrate-resistant prostate cancer. With a validated biomarker guiding patient selection, this trial has the potential to establish the first targeted combination with docetaxel in nearly two decades for mCRPC.' Design of phase 3 study Study AB22007 is a prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to confirm the efficacy and safety of docetaxel (IV 75 mg/m² plus prednisone for up to 10 cycles) plus masitinib 6.0 mg/kg/d, versus docetaxel plus placebo in metastatic castrate resistant prostate cancer (mCRPC). The study will enroll 600 patients (randomization 1:1) with confirmed mCRPC eligible to docetaxel and with a biomarker (as measured by baseline alkaline phosphatase level) indicative of less advanced metastatic disease. The study's primary endpoint will be radiographic progression free survival (rPFS), supported by overall survival as the first secondary endpoint. Masitinib is positioned in metastatic castrate resistant prostate cancer eligible to docetaxel, a high unmet medical need Masitinib is positioned in combination with docetaxel as a treatment of mCRPC patients who are eligible to docetaxel; that is to say, it is administered directly following resistance or relapse after the metastatic hormone-sensitive prostate cancer (mHSPC) treatments. While there are numerous treatments in the mHSPC treatment space, there is currently no drug registered for use in combination with standard of care treatment docetaxel in patients who have relapsed on hormone treatments, i.e., patients with mCRPC, despite docetaxel having been approved almost 20 years ago. Although localized disease is associated with high survival rates, metastatic prostate cancer still represents an unmet medical need with a 5-years survival rate of about 30% [1]. Up to 20% of men who undergo state-of-the art treatment for prostate cancer will develop CRPC within 5 years, and at least 84% of these will have metastases at the time of CRPC diagnosis [2]. Practically all patients with metastatic disease become resistant to androgen-deprivation therapy. Prostate cancer is the most common cause of cancer in men, with 137.9 new cases per 100,000 men per year [2]. The estimated prevalence of people living with prostate cancer is 113 per 100,000 [3], with approximately 15% of the patients having mCRPC eligible to chemotherapy [4]. As such, the population with mCRPC eligible to chemotherapy is around 75,000 in the EU and 50,000 in the USA. Results from study AB12003 demonstrated that the biomarker Alkaline Phosphatase predicts response of masitinib in mCRPC. The combination of masitinib plus docetaxel may provide a new first-line treatment option for mCRPC patients with low metastatic involvement Primary analysis: AB12003 was a prospective, placebo controlled, double blind, randomized, phase 3 trial, evaluating masitinib (6.0 mg/kg/d) in combination with docetaxel (IV 75 mg/m² plus prednisone for up to 10 cycles) as a first-line treatment of mCRPC. Eligible patients were chemo-naïve with confirmed mCRPC, who had progressed on previous abiraterone treatment or were indicated for docetaxel treatment, and had a ECOG ≤1. Primary analysis was performed on a pre-specified targeted subgroup, defined as patients with baseline alkaline phosphatase levels (ALP) ≤250 IU/L, and on the overall population. Primary endpoint was progression free survival (PFS) (PCWG2 definition). The study was successful if improvement in median PFS relative to control reached a 3.9% level of significance for the target subgroup (alpha split with fallback procedure to conserve overall type-I error at 5% for the overall study cohort). Primary analysis was based on 450 patients in the targeted subgroup (ALP ≤ 250 IU/L). There was a total of 712 patients in the overall study cohort. Masitinib (6.0 mg/kg/day) plus docetaxel confers a significant PFS benefit in mCRPC patients with ALP ≤ 250 IU/L. Hazard ratio of 0.79 [0.64;0.97] (p=0.0087), corresponding to a 21% reduction in risk of progression relative to control. Assessment of PFS rates was convergent with this primary outcome; 12, 18, and 24-month PFS rates showed significant improvement in favor of masitinib plus docetaxel relative to control: 1.6-fold (p=0.0035), 1.9-fold (p=0.0001) and 1.9-fold (p=0.0028), respectively. ALP as a biomarker: Importantly, a progressively greater masitinib treatment effect was observed for lower baseline ALP levels (less advanced metastatic disease), with a significant 47% reduced risk of progression in patients with ALP≤100 IU/L (hazard ratio=0.53, p=0.002). The efficacy and response of masitinib was in fact correlated to the level of ALP. The use of biomarker ALP for the confirmatory phase 3 study has been validated by FDA and EMA. The establishment of a biomarker predictive of the response to masitinib is a potentially important discovery. ALP measures the involvement in the bones and in the liver of metastasis. When used sufficiently early, masitinib in combination with docetaxel was able to slow down the progression of the metastatic cancer even resistant to hormone treatments. The masitinib plus docetaxel safety profile was acceptable with respect to control; consistent with the known masitinib profile and no new safety signals observed. Historically, there has been a high failure rate of trials studying combinations of docetaxel and new targeted agents, with study AB12003 being a rare example of a phase 3 clinical trial that showed improvement in progression-free survival (PFS) for masitinib in combination with docetaxel. Patent protection until 2042 Based on the results from AB12003 study, AB Science filed a patent application relating to methods of treating mCRPC (i.e. a secondary medical use patent) with its lead compound masitinib. The European Patent Office has granted this patent (EP4175639). It provides protection until 2042 for masitinib and related compounds for treatment of mCRPC in the patient subpopulation with low metastatic involvement (as measured by baseline alkaline phosphatase levels), which is the patient population in the approved phase 3 study of masitinib in mCRPC. Counterpart patent applications have also been filed in other major international markets, including the United States. References : [1] Cancer stat facts: prostate cancer. National Cancer Institute/ Surveillance, Epidemiology, and End Results Program. Accessed September 10, 2021. Crawford ED, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017 May;35S:S1-S13. doi: 10.1016/ [3] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. [4] Scher 2015 – PLoSONE - Symptomatic mCRPC that has not been treated with or not progressed on chemotherapy About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB ScienceFinancial Communication & Media Relations investors@ Attachment Authorisation Ph3 mRCPC VENG VF擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner

Yahoo

time3 hours ago

  • Yahoo

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner

The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneurs The founding team is developing a breakthrough technology to establish a new generation of targeted cancer therapies Committee representatives presented the award and the EUR 100,000 cash prize on Thursday, July 3, 2025 Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year's winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech's founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide. 'On behalf of the award committee and this year's expert jury panel, we would like to congratulate Isabella Attinger-Toller, Dragan Grabulovski and Philipp Spycher. Together with the expert jury, we selected the founders of Araris Biotech as winners based on their combined leadership, entrepreneurial expertise and scientific excellence. Following the successful acquisition of Araris by Taiho Pharmaceuticals, we believe this award further recognizes the founding team's continued growth and positive trajectory ahead. This trio has impressively demonstrated how a new idea, a clear focus on translation and entrepreneurial boldness can come together to launch a new generation of targeted cancer therapies,' said Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., in a joint statement. 'It was a special privilege for us to engage with such a diverse, forward-looking group of start-ups from the DACH region. Learning more about the finalists and their impressive achievements made the final decision anything but easy.' The group of finalists selected in May comprised three companies: Araris Biotech, NovaGo Therapeutics and TOLREMO therapeutics, whose founders exemplify the entrepreneurial potential and scientific diversity that characterize the life sciences sector in the DACH region. They include an impressive variety of disciplines — spanning targeted cancer therapies, regenerative neuroscience and cancer drug resistance. Following the presentation of their entrepreneurial and scientific achievements to an expert jury, Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., were announced today as the winning team and will receive a joint cash prize of EUR 100,000. "We feel very honored to have our vision and achievements recognized by the Strüngmann Award. As the founding team, we have always believed in the potential of our new technology and the value it may hold for patients. This award, in addition to the acquisition by Taiho Pharmaceuticals, is a validation of our commitment, shared journey and the hard work that has enabled our success story," said Dragan Grabulovski, Ph.D., CEO of Araris Biotech, on behalf of the founding team. The Araris Biotech founders, the experienced biotech entrepreneur Dragan Grabulovski, Ph.D., (CEO), the visionary scientist Philipp Spycher, Ph.D., (CSO) and the outstanding translational scientist Isabella Attinger-Toller, Ph.D., (CTO), can look back on one of the most successful Swiss biotech startups to be established in recent years. Spun out of the Paul Scherrer Institute (part of ETH domain) in 2019, the team developed a novel ADC linker-payload technology (AraLinQ™) that enables one-step payload attachment to off-the-shelf antibodies, without the need for prior antibody engineering. This innovative approach not only opens new possibilities in oncology, but also has potential for applications in other therapeutic areas. In only a few years, the Araris team raised over CHF 40 million, formed a strategic partnership with Chugai (Roche) and Johnson & Johnson, and achieved a landmark acquisition by Taiho Pharmaceutical in March 2025 for up to USD $1.14 billion. Through these achievements, the three winners exemplify the potential within the DACH region to successfully translate scientific excellence into global innovation. About the Strüngmann AwardThe award was established in 2024 to recognize outstanding entrepreneurs realizing revolutionary ideas in the DACH life science sector. The goal is to reward exceptional achievements with a prestigious prize and to further the development of the next generation of leaders in this space. The award was named to honor twin brothers Andreas Strüngmann, M.D., and Thomas Strüngmann, Ph.D., who are among the important entrepreneurs, visionaries and investors in the life science sector. As the founders of Hexal, they achieved extraordinary entrepreneurial success and as investors, they have continued to repeat that success for more than 20 years by building and developing leading companies across the industry, including Mainz-based BioNTech. Learn more at About Araris Biotech AGAraris Biotech is a leading biotech company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris' vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy. By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of smart missiles that deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance. Araris is a wholly owned subsidiary of Taiho Pharmaceutical following its acquisition in March 2025. For more information about our science and pipeline, please visit Media ContactTrophic CommunicationsStephanie May, Ph.D. and Anja HeuerPhone: +49 (0) 171 185 56 82Email: athos@ Attachment Strüngmann Award 2025 Goes To Araris BiotechSign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store